Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RNK08954 in Advanced Gynecologic Malignancies With KRAS G12D Mutation
NCT07848893Phase 2Not yet recruiting
- Sponsor
- Ranok Therapeutics
- Start
- Sep 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
A Phase 2 trial of RNK08954 in gynecologic malignancy, sponsored by Ranok Therapeutics. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
RNK08954
03
Conditions
gynecologic malignancy
Beyond the preview
Go deeper on NCT07848893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07848893.